Publications by authors named "Sophia Steinlein"
Article Synopsis
- Malignant pleural mesothelioma (MPM) is a type of cancer that's very hard to treat, but new drugs called chalcone derivatives, specifically CIT-026 and CIT-223, show promise in fighting it.!
- In tests, these compounds killed MPM cancer cells effectively, especially those that didn't respond to common treatments like cisplatin and pemetrexed, without hurting normal cells too much.!
- CIT-026 and CIT-223 work by messing up the proteins in cancer cells that are needed for their growth, leading to cell death, which makes these drugs potential new treatments for MPM.!
The family/class of the large B-cell lymphomas (LBCL) in the 5th edition of the World Health Organization (WHO) classification of haematolymphoid tumors (WHO-HAEM5) features only a few major changes as compared to the 4th edition. In most entities, there are only subtle changes, many of them only representing some minor modifications in diagnostic terms. Major changes have been made in the diffuse large B-cell lymphomas (DLBCL)/high-grade B-cell lymphomas (HGBL) associated with and and/or rearrangements.
View Article and Find Full Text PDFHER3 is a member of the EGF receptor family and elevated expression is associated with cancer progression and therapy resistance. HER3-specific T-cell engagers might be a suitable treatment option to circumvent the limited efficacy observed for HER3-blocking antibodies in clinical trials. In this study, we developed bispecific antibodies for T-cell retargeting to HER3-expressing tumor cells, utilizing either a single-chain diabody format (scDb) with one binding site for HER3 and one for CD3 on T-cells or a trivalent bispecific scDb-scFv fusion protein exhibiting an additional binding site for HER3.
View Article and Find Full Text PDF